Editas Medicine Stock News

Editas Medicine, Inc. (EDIT) Presents at Cowen 42nd Annual Healthcare Conference (Transcript)

The U.S. Patent and Trademark Office has ruled in favor of the Broad Institute of MIT and Harvard in a dispute over the patents around CRISPR gene-editing technology . The decision is part of a long-running legal battle brought by two universities and one of the founders of the gene-editing technique Emmanuelle Charpentier. The … Full story available on Benzinga.com

The decision is a setback for Intellia Therapeutics, Crispr Therapeutics, and Caribou Biosciences, and a win for Editas Medicine and Beam Therapeutics.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine, Inc. (NASDAQ: EDIT) sai

Editas Medicine (EDIT) has extended post-market gains to rise ~9% in early trading after the company announced a favorable decision issued by U.S

CAMBRIDGE, Mass., Feb. 28, 2022 -- Editas Medicine, Inc. , a leading genome editing company, announced today the U.S. Patent and Trademark Office issued another favorable decision to… | February 28, 2022

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued anoth

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued another favorable decision to the Broad Institute, Inc. (Broad) involving specific patents for CRISPR/Cas9 editing in human cells. Pending an appeal to the Federal Circuit, this decision ends the U.S. patent interference between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and Broad.

Editas (EDIT) reports narrower-than-expected loss in the fourth quarter of 2021 while its revenues beat estimates. Focus remains on the development of lead candidate, EDIT-101.

Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 1 1 0 Last

Editas Medicine (NASDAQ: EDIT ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 1 1 0 Last 30D 1 1 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 1 0 3M Ago 0 0 0 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $41.5 with a high of $60.00 and a low of $24.00. Below is a summary of how these 4 analysts rated Editas Medicine over the past 3 months. The greater the number of … Full story available on Benzinga.com

This article was originally published on TipRanks.com Shares of Editas Medicine, Inc. The post Editas Gains 10.1% as Q4 Results Surpass Estimates appeared first on Smarter Analyst .

Editas Medicine saw its net loss narrow ~34% in Q4 2021 as it beat on the bottom line.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th